id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-1833-0001,FDA,FDA-2026-P-1833,"Suitability Petition from Senores Pharmaceuticals, Inc.",Other,Petition(s),2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-20T00:30:44Z,,1,0,09000064b91c14eb
FDA-2026-P-1833-0002,FDA,FDA-2026-P-1833,"Acknowledgement Letter from FDA DMB to Senores Pharmaceuticals, Inc.",Other,Acknowledgement Letter/Receipt,2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-20T00:30:48Z,,0,0,09000064b91c14f0
FDA-2026-P-1833-0004,FDA,FDA-2026-P-1833,Attachment 2 - Current Electronic Edition of the Approved Drug Products with Therapeutic Equivalence Evaluations - Tolmetin Sodium,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-20T00:31:03Z,,0,0,09000064b91bf195
FDA-2026-P-1833-0003,FDA,FDA-2026-P-1833,Attachment 1 - Current Electronic Edition of the Approved Drug Products with Therapeutic Equivalence Evaluations,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-20T00:31:00Z,,0,0,09000064b91bf194
FDA-2026-P-1833-0005,FDA,FDA-2026-P-1833,Attachment 3 - Prescribing Information Tolmetin Sodium Capsules USP 400 mg,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-20T00:31:07Z,,0,0,09000064b91bf196
FDA-2026-P-1833-0006,FDA,FDA-2026-P-1833,Attachment 4 - Proposed labeling for Tolmetin Sodium Capsules 600 mg,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-20T00:31:10Z,,0,0,09000064b91bf197